Lead Product(s) : HG004
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HuidaGene Receives Orphan Drug Designation for Gene Therapy of Blindness
Details : HG004 is a gene replacement therapy drug which uses the recombinant non-adeno-associated virus serotype 2 vector to deliver a functional human RPE65 gene to the retina to restore, treat, and prevent blindness of children and adults with RPE65 mutation-as...
Product Name : HG004
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 04, 2023
Lead Product(s) : HG004
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HG004
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HG004 is an ophthalmic injection intended for the treatment of RPE65 gene mutation-related retinopathy. Based on direct preclinical comparative studies of HG004 and AAV2 in retinal function, HG004 is at least 10 times more efficient at transducing retina...
Product Name : HG004
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 27, 2023
Lead Product(s) : HG004
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARVN601
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : University of Hong Kong
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ARVN601 Neuroprotection, in the form of non-IOP-related interventions to prevent or delay glaucomatous neurodegeneration, has been underscored to be an unmet need in the management of glaucoma ever since the 2010 World Glaucoma Association Consensus Meet...
Product Name : ARVN601
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 07, 2021
Lead Product(s) : ARVN601
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : University of Hong Kong
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : RB-RQ007
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Capital Venture Capital Fund
Deal Size : $66.0 million
Deal Type : Series C Financing
Suzhou Ribo Life Science Completes $66 Million C Round for siRNA Portfolio
Details : The funding is inted boost company's siRNA Portfolio.
Product Name : RB-RQ007
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : RB-RQ007
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Capital Venture Capital Fund
Deal Size : $66.0 million
Deal Type : Series C Financing